SeaBridge Investment Advisors’s CRISPR Therapeutics CRSP Stock Holding History

SeaBridge Investment Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-300	Closed	-$25K	–	156
2020 Q3	$25K	Hold	300	–	–	0.01%	194
2020 Q2	$22K	Hold	300	–	–	0.01%	199
2020 Q1	$13K	Hold	300	–	–	0.01%	214
2019 Q4	$18K	Hold	300	–	–	0.01%	212
2019 Q3	$12K	Hold	300	–	–	﹤0.01%	236
2019 Q2	$14K	Hold	300	–	–	﹤0.01%	228
2019 Q1	$11K	Hold	300	–	–	﹤0.01%	227
2018 Q4	$9K	Hold	300	–	–	﹤0.01%	223
2018 Q3	$13K	Hold	300	–	–	﹤0.01%	213
2018 Q2	$18K	Hold	300	–	–	﹤0.01%	209
2018 Q1	$14K	Buy	+300	New	+$12.4K	﹤0.01%	217

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SeaBridge Investment Advisors's CRSP Position: Q4 2020 in Review

SeaBridge Investment Advisors sold out of CRISPR Therapeutics (CRSP) in Q4 2020, closing a stake of 300 shares — an estimated $25K sold.

SeaBridge Investment Advisors first reported a position in CRSP in Q1 2018 and held it in 11 quarters. The position peaked at $25K in Q3 2020. 412 funds tracked by Wall St. Rank hold CRSP as of Q4 2020.

SeaBridge Investment Advisors reported no remaining CRISPR Therapeutics position as of Q4 2020 after selling out during the quarter.
SeaBridge Investment Advisors sold 300 CRISPR Therapeutics shares in Q4 2020, an estimated $25K.
SeaBridge Investment Advisors first reported a position in CRISPR Therapeutics in Q1 2018 and held it in 11 quarters.
SeaBridge Investment Advisors's CRISPR Therapeutics position peaked at $25K in Q3 2020.
412 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2020.

Based on SeaBridge Investment Advisors's 13F filing for Q4 2020, filed 9 Feb 2021.